Generic Medicine Info
Should be taken with food. Best taken w/ meals. Take before meals if dry mouth occurs, after meals if drooling/nausea occurs. Take at the same time each day.
Special Precautions
Patient w/ arteriosclerosis, history of drug idiosyncrasy. CV disease, glaucoma, GI obstruction, prostatic hyperplasia and/or urinary stricture. Not intended for treatment of tardive dyskinesia. Avoid abrupt withdrawal. Hepatic and renal impairment. Elderly. Pregnancy and lactation. Patient Counselling May impair mental or physical abilities e.g. operating machinery or driving. Monitoring Parameters Perform gonioscopic examination prior to initiation of therapy. Monitor intraocular pressure at regular intervals during prolonged treatment.
Adverse Reactions
Dryness of the mouth, nausea, constipation, vomiting, dizziness, drowsiness, headache, blurred vision, mydriasis, nervousness, tachycardia, urinary hesitancy or retention, increased intraocular tension, angle-closure glaucoma, weakness, rashes, dilatation of the colon, paralytic ileus, and suppurative parotitis. Rarely, psychiatric disturbances (e.g. delusion, amnesia, depersonalization, sense of unreality, paranoia).
Drug Interactions
Increased antimuscarinic side effects w/ phenothiazines, clozapine, antihistamines, disopyramide, nefopam and amantadine. Synergistic effect when concomitantly used w/ TCAs. Concurrent admin w/ MAOIs may cause dry mouth, blurred vision, urinary hesitancy or retention and constipation. May antagonise effect of metoclopramide and domperidone on GI function. Reduced absorption of levodopa. May antagonise effect of parasympathomimetics.
CIMS Class
Antiparkinsonian Drugs
ATC Classification
N04AA01 - trihexyphenidyl ; Belongs to the class of tertiary amines anticholinergic agents. Used in the management of Parkinson's disease.
Disclaimer: This information is independently developed by CIMS based on trihexyphenidyl from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in